Showing all 6 results
The Cancer Antigen 72-4 (CA 72-4) Test is a diagnostic blood test used to detect and monitor gastrointestinal cancers, particularly gastric and colorectal cancer. It measures CA 72-4, a tumor-associated glycoprotein, aiding in early detection, treatment monitoring, and recurrence assessment.
Sample Type : Serum
Methodology : TBA
TAT : 7 Days
FEMALE CANCER MARKERS PACKAGE
The HER-2/NEU – FISH Test is a highly precise diagnostic tool used to detect HER-2 gene amplification in breast cancer and other malignancies. Utilizing Fluorescence In Situ Hybridization (FISH) technology, it provides accurate, reliable, and early detection of HER-2 status, which is crucial for determining targeted therapy eligibility, such as Herceptin (trastuzumab) treatment.
Immunohistochemical (IHC) Stain tests are advanced diagnostic tools used to detect specific antigens in tissue samples, aiding in disease diagnosis, particularly cancer. These tests utilize highly specific antibodies to identify cellular markers, enabling precise differentiation between tissue types and disease states.
Sample Type : Paraffin Embedded Block/Charged Slides
Methodology : Immunohistochemical
TAT : 5 days
The PD-L1 (22C3) Dako CPS (IHC) test is an immunohistochemistry (IHC) assay designed to assess PD-L1 expression in tumor and immune cells using the Combined Positive Score (CPS). It is FDA-approved as a companion diagnostic for multiple cancer therapies, ensuring precise patient selection for immune checkpoint inhibitors. The test utilizes the 22C3 monoclonal antibody, providing high sensitivity and specificity in detecting PD-L1 expression. Its standardized scoring system (CPS) enhances reproducibility and clinical decision-making, making it a trusted tool for oncologists. The Dako platform ensures consistent, high-quality staining, supporting accurate and reliable results for personalized cancer treatment.
The **Ros1 – Fish Test** is a highly sensitive and reliable fluorescence in situ hybridization (FISH) assay designed for the detection of **ROS1 gene rearrangements** in tumor samples. This test is crucial for identifying patients who may benefit from targeted therapies, particularly in **non-small cell lung cancer (NSCLC)**. Key features include **high specificity and accuracy**, rapid turnaround time, and **direct visualization of gene rearrangements** at the cellular level. Its benefits include **early and precise diagnosis**, enabling personalized treatment decisions and improving patient outcomes. The **unique selling point** of the Ros1 – Fish Test is its **proven clinical utility in guiding targeted therapy selection**, making it an essential tool for oncologists and pathologists in precision medicine.
